Antibody Information
General Information of This Antibody
| Antibody ID | ANI0CQDJU |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | 1F9DS |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Murine IgG1 |
|||||
| Antigen Name | CD276 antigen (CD276) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
WO2020063676A1 ADC-30 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.31% (Day 18) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | U87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 45.23% (Day 18) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | U87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
WO2020063676A1 ADC-31 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 39.22% (Day 18) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | U87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.24% (Day 18) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | U87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
WO2020063676A1 ADC-26 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 49.10% (Day 22) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | U87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
WO2020063676A1 ADC-28 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 56.20% (Day 28) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | Detroit 562 CDX model | ||||
| In Vitro Model | Pharyngeal squamous cell carcinoma | Detroit 562 cells | CVCL_1171 | ||
WO2020063676A1 ADC-27 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 63.30% (Day 22) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | U87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
WO2020063676A1 ADC-29 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 72.27% (Day 28) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | Detroit 562 CDX model | ||||
| In Vitro Model | Pharyngeal squamous cell carcinoma | Detroit 562 cells | CVCL_1171 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.